Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: Medpace Holdings (MEDP), McKesson (MCK) and Glaukos (GKOS)
Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $145
Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $135
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
Stifel Nicolaus Issues a Buy Rating on Glaukos (GKOS)
Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $135
Piper Sandler Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $140
Piper Sandler Remains a Buy on Glaukos (GKOS)
Glaukos Receives Buy Rating Amidst Promising Phase 3 Epioxa Trial Results and Growth Prospects
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $152
Glaukos Is Maintained at Buy by Truist Securities
Glaukos Analyst Ratings
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $139
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $139
Buy Rating on Glaukos: IDose's Market Potential and Strategic Advantages Outshine Ripple's RTC-620
Glaukos's Market Position and Mid-Term Growth Prospects Amidst Increased Competition: A Hold Rating Analysis
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $145
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $139
BTIG Sticks to Their Buy Rating for Glaukos (GKOS)